 Thomas Morrison
Concepts (472)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chikungunya virus | 30 | 2024 | 61 | 10.780 |
Why?
| | Chikungunya Fever | 27 | 2024 | 61 | 8.840 |
Why?
| | Alphavirus Infections | 28 | 2022 | 41 | 8.590 |
Why?
| | Ross River virus | 18 | 2021 | 22 | 4.560 |
Why?
| | Viral Envelope Proteins | 11 | 2022 | 73 | 2.610 |
Why?
| | Interferon Type I | 9 | 2021 | 128 | 2.120 |
Why?
| | Host-Pathogen Interactions | 9 | 2021 | 295 | 2.100 |
Why?
| | Alphavirus | 9 | 2022 | 17 | 1.890 |
Why?
| | Virus Replication | 22 | 2022 | 395 | 1.740 |
Why?
| | Virulence Factors | 5 | 2018 | 139 | 1.530 |
Why?
| | Receptors, Immunologic | 3 | 2023 | 198 | 1.510 |
Why?
| | Lymph Nodes | 4 | 2024 | 415 | 1.470 |
Why?
| | Disease Models, Animal | 23 | 2022 | 3498 | 1.460 |
Why?
| | Antibodies, Viral | 15 | 2022 | 520 | 1.400 |
Why?
| | Animals | 83 | 2024 | 31565 | 1.370 |
Why?
| | Mice | 48 | 2023 | 14843 | 1.320 |
Why?
| | Adaptive Immunity | 5 | 2020 | 154 | 1.310 |
Why?
| | Viral Proteins | 12 | 2019 | 281 | 1.290 |
Why?
| | Viral Load | 11 | 2021 | 405 | 1.230 |
Why?
| | Antiviral Agents | 8 | 2021 | 642 | 1.200 |
Why?
| | Newcastle disease virus | 13 | 2001 | 17 | 1.190 |
Why?
| | Mice, Inbred C57BL | 26 | 2021 | 4680 | 1.180 |
Why?
| | Viruses | 4 | 2022 | 94 | 1.160 |
Why?
| | Viral Vaccines | 4 | 2022 | 88 | 1.150 |
Why?
| | Encephalitis Virus, Venezuelan Equine | 4 | 2021 | 4 | 1.140 |
Why?
| | Arthritis | 4 | 2020 | 109 | 1.050 |
Why?
| | Monocytes | 3 | 2020 | 503 | 1.050 |
Why?
| | Arginase | 3 | 2015 | 26 | 1.030 |
Why?
| | Viremia | 3 | 2023 | 122 | 1.020 |
Why?
| | B-Lymphocytes | 4 | 2020 | 762 | 0.980 |
Why?
| | Antibodies, Neutralizing | 9 | 2023 | 222 | 0.950 |
Why?
| | Joints | 4 | 2020 | 83 | 0.900 |
Why?
| | Immunity, Innate | 7 | 2022 | 720 | 0.890 |
Why?
| | Interferon Regulatory Factors | 2 | 2022 | 31 | 0.860 |
Why?
| | RNA Virus Infections | 3 | 2019 | 11 | 0.850 |
Why?
| | Virulence | 10 | 2021 | 228 | 0.850 |
Why?
| | Kupffer Cells | 2 | 2021 | 45 | 0.850 |
Why?
| | Virion | 3 | 2022 | 73 | 0.840 |
Why?
| | Musculoskeletal Diseases | 2 | 2016 | 54 | 0.830 |
Why?
| | Inflammation | 9 | 2023 | 2464 | 0.810 |
Why?
| | Macrophages | 6 | 2022 | 1259 | 0.800 |
Why?
| | Adaptor Proteins, Signal Transducing | 5 | 2021 | 367 | 0.800 |
Why?
| | Mice, Knockout | 17 | 2022 | 2562 | 0.790 |
Why?
| | Neutrophils | 2 | 2020 | 1089 | 0.770 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2021 | 686 | 0.750 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2020 | 90 | 0.730 |
Why?
| | Viral Fusion Proteins | 8 | 2001 | 20 | 0.710 |
Why?
| | Capsid Proteins | 3 | 2020 | 68 | 0.710 |
Why?
| | RNA Viruses | 2 | 2019 | 28 | 0.710 |
Why?
| | Myositis | 3 | 2012 | 44 | 0.690 |
Why?
| | RNA, Viral | 13 | 2021 | 565 | 0.690 |
Why?
| | Viral Nonstructural Proteins | 3 | 2021 | 54 | 0.690 |
Why?
| | Complement System Proteins | 4 | 2023 | 281 | 0.690 |
Why?
| | Quinolones | 1 | 2021 | 97 | 0.690 |
Why?
| | NADPH Oxidase 2 | 1 | 2020 | 42 | 0.680 |
Why?
| | O'nyong-nyong Virus | 1 | 2019 | 4 | 0.670 |
Why?
| | Herpesvirus 4, Human | 4 | 2004 | 124 | 0.670 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2020 | 157 | 0.660 |
Why?
| | Dendritic Cells | 2 | 2021 | 435 | 0.640 |
Why?
| | Leishmania major | 1 | 2018 | 6 | 0.630 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2018 | 7 | 0.630 |
Why?
| | Myeloid Cells | 3 | 2015 | 126 | 0.620 |
Why?
| | Muscle, Skeletal | 9 | 2020 | 1468 | 0.620 |
Why?
| | Trans-Activators | 4 | 2004 | 366 | 0.590 |
Why?
| | Osteoarthritis | 1 | 2020 | 169 | 0.580 |
Why?
| | Pathogen-Associated Molecular Pattern Molecules | 1 | 2017 | 6 | 0.560 |
Why?
| | Chronic Disease | 4 | 2019 | 1577 | 0.550 |
Why?
| | Superoxide Dismutase | 1 | 2018 | 305 | 0.550 |
Why?
| | Mutation, Missense | 2 | 2019 | 294 | 0.540 |
Why?
| | Disease Outbreaks | 4 | 2023 | 305 | 0.530 |
Why?
| | Gene Deletion | 3 | 2018 | 356 | 0.530 |
Why?
| | Zika Virus | 1 | 2017 | 61 | 0.530 |
Why?
| | Amino Acid Substitution | 3 | 2014 | 261 | 0.530 |
Why?
| | Zika Virus Infection | 1 | 2017 | 85 | 0.510 |
Why?
| | Immunization | 4 | 2024 | 397 | 0.500 |
Why?
| | Cell Line | 18 | 2021 | 2629 | 0.490 |
Why?
| | Complement Activation | 5 | 2018 | 337 | 0.480 |
Why?
| | Humans | 63 | 2023 | 114045 | 0.480 |
Why?
| | Endothelial Cells | 4 | 2024 | 677 | 0.430 |
Why?
| | Tyrosine | 3 | 2013 | 210 | 0.430 |
Why?
| | Arthralgia | 1 | 2013 | 46 | 0.420 |
Why?
| | Membrane Fusion | 3 | 2001 | 38 | 0.420 |
Why?
| | Histidine | 1 | 2013 | 57 | 0.420 |
Why?
| | Immunity, Cellular | 1 | 2014 | 247 | 0.420 |
Why?
| | DNA-Binding Proteins | 3 | 2004 | 1311 | 0.400 |
Why?
| | Sindbis Virus | 4 | 2017 | 9 | 0.390 |
Why?
| | Severe Acute Respiratory Syndrome | 4 | 2018 | 13 | 0.380 |
Why?
| | Antibodies, Monoclonal | 4 | 2020 | 1257 | 0.380 |
Why?
| | Tenosynovitis | 1 | 2010 | 11 | 0.360 |
Why?
| | Emergency Responders | 2 | 2021 | 33 | 0.360 |
Why?
| | Mice, Transgenic | 4 | 2021 | 1947 | 0.330 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2021 | 170 | 0.330 |
Why?
| | Up-Regulation | 1 | 2012 | 802 | 0.330 |
Why?
| | Vero Cells | 9 | 2021 | 63 | 0.330 |
Why?
| | T-Lymphocytes | 2 | 2019 | 1735 | 0.320 |
Why?
| | Lymphoid Tissue | 2 | 2019 | 62 | 0.310 |
Why?
| | HN Protein | 3 | 1993 | 5 | 0.310 |
Why?
| | Macrophage-1 Antigen | 1 | 2008 | 25 | 0.310 |
Why?
| | Virus Diseases | 1 | 2011 | 195 | 0.310 |
Why?
| | Spike Glycoprotein, Coronavirus | 4 | 2022 | 92 | 0.310 |
Why?
| | Phenylalanine | 2 | 2022 | 57 | 0.300 |
Why?
| | Signal Transduction | 9 | 2021 | 4501 | 0.300 |
Why?
| | Arboviruses | 1 | 2008 | 10 | 0.300 |
Why?
| | Cell Membrane | 4 | 2018 | 670 | 0.300 |
Why?
| | Arbovirus Infections | 1 | 2008 | 17 | 0.290 |
Why?
| | Complement C3 | 4 | 2018 | 188 | 0.290 |
Why?
| | Cricetinae | 6 | 2020 | 252 | 0.290 |
Why?
| | Adoptive Transfer | 2 | 2020 | 194 | 0.290 |
Why?
| | Adenoviridae | 2 | 2021 | 184 | 0.280 |
Why?
| | Mutagenesis, Site-Directed | 7 | 2010 | 345 | 0.280 |
Why?
| | Epitopes | 2 | 2020 | 434 | 0.280 |
Why?
| | Phosphoproteins | 3 | 2016 | 293 | 0.260 |
Why?
| | West Nile virus | 2 | 2016 | 36 | 0.260 |
Why?
| | Cytokines | 5 | 2020 | 1824 | 0.250 |
Why?
| | Arthritis, Infectious | 1 | 2006 | 49 | 0.240 |
Why?
| | Mice, Inbred BALB C | 4 | 2018 | 1144 | 0.240 |
Why?
| | Down-Regulation | 2 | 2004 | 594 | 0.240 |
Why?
| | Immunoglobulin G | 4 | 2022 | 766 | 0.240 |
Why?
| | Macaca mulatta | 2 | 2023 | 131 | 0.230 |
Why?
| | Membrane Proteins | 2 | 2022 | 1016 | 0.230 |
Why?
| | Immunoassay | 2 | 2021 | 95 | 0.230 |
Why?
| | Genome, Viral | 4 | 2019 | 118 | 0.220 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2023 | 26 | 0.220 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2004 | 140 | 0.210 |
Why?
| | Lymphocyte Activation | 2 | 2018 | 1036 | 0.210 |
Why?
| | Killer Cells, Natural | 3 | 2019 | 380 | 0.210 |
Why?
| | Robotics | 1 | 2023 | 76 | 0.210 |
Why?
| | Antigens, Viral | 2 | 2021 | 176 | 0.200 |
Why?
| | Arthritis, Rheumatoid | 1 | 2010 | 1002 | 0.200 |
Why?
| | Robotic Surgical Procedures | 1 | 2023 | 86 | 0.200 |
Why?
| | Protein Biosynthesis | 4 | 2019 | 386 | 0.190 |
Why?
| | Salmonella | 1 | 2022 | 54 | 0.190 |
Why?
| | NF-kappa B | 2 | 2008 | 636 | 0.190 |
Why?
| | Transcriptional Activation | 2 | 2022 | 337 | 0.190 |
Why?
| | Vaccines, Attenuated | 1 | 2022 | 113 | 0.190 |
Why?
| | Base Sequence | 9 | 2010 | 2114 | 0.190 |
Why?
| | Benzene Derivatives | 1 | 2021 | 8 | 0.190 |
Why?
| | Gynecology | 1 | 2023 | 163 | 0.190 |
Why?
| | Cell Proliferation | 2 | 2018 | 2173 | 0.190 |
Why?
| | Oligosaccharides | 1 | 2001 | 46 | 0.180 |
Why?
| | Mice, Mutant Strains | 1 | 2021 | 271 | 0.180 |
Why?
| | Horses | 1 | 2021 | 96 | 0.180 |
Why?
| | Interferon-gamma | 3 | 2010 | 719 | 0.180 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2004 | 393 | 0.180 |
Why?
| | Convalescence | 1 | 2021 | 15 | 0.180 |
Why?
| | Protein Domains | 1 | 2022 | 207 | 0.180 |
Why?
| | Specimen Handling | 1 | 2022 | 153 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2001 | 72 | 0.180 |
Why?
| | Influenza, Human | 2 | 2020 | 543 | 0.180 |
Why?
| | Oocytes | 2 | 2004 | 169 | 0.180 |
Why?
| | Receptors, Mitogen | 1 | 2020 | 8 | 0.170 |
Why?
| | Culicidae | 2 | 2013 | 29 | 0.170 |
Why?
| | Lectins, C-Type | 1 | 2020 | 60 | 0.170 |
Why?
| | Type C Phospholipases | 1 | 2000 | 65 | 0.170 |
Why?
| | Xenopus | 1 | 2000 | 94 | 0.170 |
Why?
| | Mutation | 5 | 2021 | 3338 | 0.170 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2022 | 285 | 0.170 |
Why?
| | Interferon Regulatory Factor-3 | 2 | 2017 | 17 | 0.170 |
Why?
| | Glycoproteins | 2 | 2016 | 304 | 0.170 |
Why?
| | Blood Donors | 1 | 2021 | 84 | 0.170 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2019 | 18 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 186 | 0.170 |
Why?
| | Encephalomyelitis, Venezuelan Equine | 1 | 2019 | 1 | 0.170 |
Why?
| | Laparoscopy | 1 | 2023 | 395 | 0.170 |
Why?
| | STAT1 Transcription Factor | 2 | 2010 | 63 | 0.170 |
Why?
| | Benzylamines | 1 | 2019 | 39 | 0.160 |
Why?
| | RNA, Double-Stranded | 1 | 2019 | 44 | 0.160 |
Why?
| | Blotting, Western | 3 | 2015 | 1143 | 0.160 |
Why?
| | Homeodomain Proteins | 3 | 2014 | 465 | 0.160 |
Why?
| | Primates | 2 | 2017 | 110 | 0.160 |
Why?
| | Molecular Sequence Data | 7 | 2010 | 2783 | 0.160 |
Why?
| | Lung | 5 | 2023 | 3521 | 0.160 |
Why?
| | Leishmania donovani | 1 | 2018 | 3 | 0.160 |
Why?
| | Parasite Load | 1 | 2018 | 7 | 0.160 |
Why?
| | Viral Tropism | 2 | 2019 | 24 | 0.160 |
Why?
| | Progesterone | 1 | 2000 | 232 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1128 | 0.160 |
Why?
| | Venules | 1 | 2018 | 13 | 0.150 |
Why?
| | Female | 17 | 2021 | 59324 | 0.150 |
Why?
| | Chemokine CCL21 | 1 | 2018 | 13 | 0.150 |
Why?
| | Endothelium, Lymphatic | 1 | 2018 | 12 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 959 | 0.150 |
Why?
| | src-Family Kinases | 1 | 2019 | 88 | 0.150 |
Why?
| | Genes, Viral | 5 | 2006 | 89 | 0.150 |
Why?
| | RNA, Messenger | 3 | 2019 | 2550 | 0.150 |
Why?
| | Ovalbumin | 1 | 2018 | 161 | 0.150 |
Why?
| | Interferon Regulatory Factor-7 | 1 | 2017 | 4 | 0.150 |
Why?
| | Stromal Cells | 1 | 2018 | 96 | 0.150 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2017 | 11 | 0.150 |
Why?
| | Aedes | 2 | 2019 | 55 | 0.150 |
Why?
| | Hindlimb | 2 | 2010 | 130 | 0.150 |
Why?
| | Antigens, Ly | 1 | 2017 | 45 | 0.150 |
Why?
| | Methotrexate | 1 | 2019 | 227 | 0.150 |
Why?
| | Receptors, CCR2 | 1 | 2017 | 28 | 0.150 |
Why?
| | Diphtheria Toxin | 1 | 2017 | 51 | 0.150 |
Why?
| | Lysine | 1 | 2019 | 241 | 0.140 |
Why?
| | Gene Expression | 4 | 2015 | 1417 | 0.140 |
Why?
| | Protein Processing, Post-Translational | 4 | 2012 | 399 | 0.140 |
Why?
| | Polysaccharides | 1 | 2018 | 78 | 0.140 |
Why?
| | Transfection | 6 | 2009 | 863 | 0.140 |
Why?
| | HeLa Cells | 5 | 2023 | 563 | 0.140 |
Why?
| | Mutant Proteins | 2 | 2014 | 95 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 137 | 0.140 |
Why?
| | Mannose-Binding Lectin | 2 | 2018 | 20 | 0.140 |
Why?
| | Toll-Like Receptors | 1 | 2017 | 167 | 0.140 |
Why?
| | Bacterial Proteins | 1 | 2022 | 735 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 437 | 0.130 |
Why?
| | Antirheumatic Agents | 1 | 2019 | 255 | 0.130 |
Why?
| | Oxidative Stress | 1 | 2022 | 1068 | 0.130 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2016 | 43 | 0.130 |
Why?
| | Cytoplasm | 2 | 2017 | 255 | 0.130 |
Why?
| | Male | 11 | 2021 | 55396 | 0.130 |
Why?
| | alpha-Synuclein | 1 | 2015 | 21 | 0.130 |
Why?
| | Schistosomiasis mansoni | 1 | 2015 | 19 | 0.130 |
Why?
| | Schistosoma mansoni | 1 | 2015 | 33 | 0.130 |
Why?
| | RNA Caps | 1 | 2015 | 31 | 0.120 |
Why?
| | Vaccination | 2 | 2021 | 1202 | 0.120 |
Why?
| | Epidemiological Monitoring | 1 | 2015 | 46 | 0.120 |
Why?
| | Histocompatibility Antigen H-2D | 1 | 2014 | 21 | 0.120 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2015 | 35 | 0.120 |
Why?
| | Communicable Disease Control | 1 | 2015 | 67 | 0.120 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2015 | 113 | 0.120 |
Why?
| | Friend murine leukemia virus | 1 | 2015 | 29 | 0.120 |
Why?
| | Cytidine Deaminase | 1 | 2015 | 57 | 0.120 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 1 | 2014 | 20 | 0.110 |
Why?
| | Flow Cytometry | 2 | 2015 | 1075 | 0.110 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2014 | 24 | 0.110 |
Why?
| | Animal Structures | 1 | 2014 | 8 | 0.110 |
Why?
| | Gene Expression Regulation, Viral | 2 | 2012 | 80 | 0.110 |
Why?
| | Hospitalization | 1 | 2022 | 1762 | 0.110 |
Why?
| | Pandemics | 3 | 2023 | 1310 | 0.110 |
Why?
| | Glycosaminoglycans | 1 | 2013 | 79 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 784 | 0.110 |
Why?
| | Fibroblasts | 1 | 2018 | 834 | 0.110 |
Why?
| | Amino Acids | 1 | 2016 | 445 | 0.100 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 373 | 0.100 |
Why?
| | ELAV Proteins | 1 | 2012 | 12 | 0.100 |
Why?
| | Arthritis, Experimental | 1 | 2014 | 130 | 0.100 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 990 | 0.100 |
Why?
| | Amino Acid Sequence | 6 | 1994 | 1981 | 0.100 |
Why?
| | Mycobacterium tuberculosis | 1 | 2015 | 269 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2016 | 694 | 0.100 |
Why?
| | Arthritis, Reactive | 1 | 2012 | 8 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 1815 | 0.100 |
Why?
| | Structure-Activity Relationship | 3 | 2021 | 499 | 0.090 |
Why?
| | Synovial Fluid | 2 | 2012 | 56 | 0.090 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 5 | 0.090 |
Why?
| | Transcription, Genetic | 3 | 2004 | 1310 | 0.090 |
Why?
| | Newcastle Disease | 1 | 1990 | 1 | 0.090 |
Why?
| | Avian Leukosis Virus | 1 | 1990 | 6 | 0.090 |
Why?
| | Reassortant Viruses | 1 | 2010 | 7 | 0.090 |
Why?
| | Protective Agents | 1 | 2011 | 37 | 0.090 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 137 | 0.090 |
Why?
| | DNA, Viral | 5 | 1993 | 349 | 0.090 |
Why?
| | Chickens | 1 | 1990 | 180 | 0.090 |
Why?
| | Immunotherapy | 1 | 2014 | 473 | 0.090 |
Why?
| | Receptors, Interferon | 1 | 2010 | 47 | 0.090 |
Why?
| | Genetic Vectors | 3 | 2021 | 287 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 138 | 0.080 |
Why?
| | COS Cells | 2 | 2001 | 175 | 0.080 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 14 | 0.080 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2009 | 32 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 73 | 0.080 |
Why?
| | Time Factors | 2 | 2021 | 6077 | 0.080 |
Why?
| | Calgranulin B | 1 | 2008 | 7 | 0.080 |
Why?
| | Flavivirus Infections | 1 | 2008 | 9 | 0.070 |
Why?
| | Flavivirus | 1 | 2008 | 16 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 787 | 0.070 |
Why?
| | Cricetulus | 3 | 2014 | 97 | 0.070 |
Why?
| | Small Molecule Libraries | 2 | 2019 | 79 | 0.070 |
Why?
| | Promoter Regions, Genetic | 2 | 2009 | 1131 | 0.070 |
Why?
| | Histocytochemistry | 1 | 2007 | 78 | 0.070 |
Why?
| | Insect Vectors | 1 | 2006 | 27 | 0.070 |
Why?
| | Serum | 1 | 2007 | 57 | 0.070 |
Why?
| | Cell Survival | 2 | 2021 | 1014 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 1880 | 0.070 |
Why?
| | Mitochondrial Proteins | 1 | 2008 | 213 | 0.060 |
Why?
| | Glycosylation | 2 | 2006 | 130 | 0.060 |
Why?
| | Organ Specificity | 1 | 2006 | 266 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 743 | 0.060 |
Why?
| | Phosphorylation | 4 | 2012 | 1558 | 0.060 |
Why?
| | Chick Embryo | 4 | 1992 | 122 | 0.060 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2004 | 52 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2008 | 673 | 0.060 |
Why?
| | Genes, Immediate-Early | 1 | 2004 | 15 | 0.060 |
Why?
| | Brain | 1 | 2015 | 2355 | 0.060 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2004 | 109 | 0.060 |
Why?
| | Plasmids | 3 | 1991 | 343 | 0.060 |
Why?
| | I-kappa B Proteins | 1 | 2004 | 80 | 0.060 |
Why?
| | Transcription Factor RelA | 1 | 2004 | 80 | 0.060 |
Why?
| | HEK293 Cells | 2 | 2019 | 590 | 0.060 |
Why?
| | Immediate-Early Proteins | 1 | 2004 | 52 | 0.060 |
Why?
| | CHO Cells | 2 | 2014 | 137 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2004 | 147 | 0.060 |
Why?
| | Cell Line, Transformed | 1 | 2004 | 133 | 0.050 |
Why?
| | Centrifugation, Density Gradient | 2 | 2001 | 40 | 0.050 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2023 | 51 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 147 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2023 | 103 | 0.050 |
Why?
| | Binding Sites | 2 | 2021 | 1166 | 0.050 |
Why?
| | Cloning, Molecular | 3 | 2008 | 522 | 0.050 |
Why?
| | Bone and Bones | 1 | 2006 | 277 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 613 | 0.050 |
Why?
| | Coculture Techniques | 1 | 2023 | 198 | 0.050 |
Why?
| | Body Weight | 1 | 2007 | 868 | 0.050 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2023 | 154 | 0.050 |
Why?
| | Mitochondria | 1 | 2008 | 744 | 0.050 |
Why?
| | Keratinocytes | 1 | 2004 | 215 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2023 | 112 | 0.050 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2022 | 51 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1206 | 0.050 |
Why?
| | Basal Ganglia Diseases | 1 | 2001 | 8 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2004 | 552 | 0.050 |
Why?
| | Australia | 1 | 2022 | 205 | 0.050 |
Why?
| | Central Nervous System Vascular Malformations | 1 | 2001 | 23 | 0.050 |
Why?
| | Colorado | 2 | 2021 | 4090 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 101 | 0.050 |
Why?
| | Cross Protection | 1 | 2021 | 4 | 0.050 |
Why?
| | Cross Reactions | 1 | 2021 | 118 | 0.050 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 1 | 2021 | 20 | 0.050 |
Why?
| | Microsomes, Liver | 1 | 2021 | 54 | 0.050 |
Why?
| | Half-Life | 1 | 2021 | 141 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2537 | 0.050 |
Why?
| | Immunity | 1 | 2001 | 121 | 0.050 |
Why?
| | Microspheres | 1 | 2021 | 123 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 101 | 0.050 |
Why?
| | Metformin | 1 | 2004 | 274 | 0.040 |
Why?
| | Tyrphostins | 1 | 2000 | 13 | 0.040 |
Why?
| | Phosphotyrosine | 1 | 2000 | 33 | 0.040 |
Why?
| | Genetic Engineering | 1 | 2021 | 80 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 245 | 0.040 |
Why?
| | Giant Cells | 2 | 1998 | 21 | 0.040 |
Why?
| | Phosphoserine | 1 | 2000 | 33 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2001 | 396 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2004 | 965 | 0.040 |
Why?
| | Kinetics | 2 | 2013 | 1547 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2015 | 3861 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 522 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2000 | 139 | 0.040 |
Why?
| | NIH 3T3 Cells | 1 | 2019 | 137 | 0.040 |
Why?
| | Mosquito Vectors | 1 | 2019 | 21 | 0.040 |
Why?
| | Protein Transport | 2 | 2012 | 391 | 0.040 |
Why?
| | Poly I-C | 1 | 2018 | 51 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2000 | 771 | 0.040 |
Why?
| | Interferon-beta | 2 | 2009 | 79 | 0.040 |
Why?
| | Trypsin | 1 | 1998 | 66 | 0.040 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2018 | 23 | 0.040 |
Why?
| | Molecular Structure | 1 | 2019 | 434 | 0.040 |
Why?
| | Autocrine Communication | 1 | 2018 | 42 | 0.040 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 123 | 0.040 |
Why?
| | Spleen | 1 | 2019 | 485 | 0.040 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2018 | 44 | 0.040 |
Why?
| | Length of Stay | 1 | 2022 | 957 | 0.040 |
Why?
| | Paracrine Communication | 1 | 2018 | 55 | 0.040 |
Why?
| | Chemokines | 1 | 2018 | 215 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2019 | 328 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1690 | 0.030 |
Why?
| | Capsid | 1 | 2017 | 74 | 0.030 |
Why?
| | Eukaryotic Initiation Factors | 1 | 2016 | 9 | 0.030 |
Why?
| | Biological Transport | 3 | 1992 | 374 | 0.030 |
Why?
| | Virus Assembly | 1 | 2017 | 66 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2016 | 36 | 0.030 |
Why?
| | Ouabain | 1 | 2016 | 15 | 0.030 |
Why?
| | Digoxin | 1 | 2016 | 26 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2009 | 534 | 0.030 |
Why?
| | Transcription Factors | 1 | 2004 | 1526 | 0.030 |
Why?
| | Carbonyl Cyanide m-Chlorophenyl Hydrazone | 2 | 1985 | 4 | 0.030 |
Why?
| | Monensin | 2 | 1985 | 6 | 0.030 |
Why?
| | Drug Resistance, Viral | 1 | 2016 | 99 | 0.030 |
Why?
| | Granuloma | 1 | 2015 | 82 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1836 | 0.030 |
Why?
| | Apoptosis | 1 | 2004 | 2349 | 0.030 |
Why?
| | Viral Plaque Assay | 2 | 1992 | 24 | 0.030 |
Why?
| | International Cooperation | 1 | 2015 | 169 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 926 | 0.030 |
Why?
| | Calcium | 1 | 2000 | 1089 | 0.030 |
Why?
| | RNA Stability | 1 | 2015 | 90 | 0.030 |
Why?
| | Vesicular stomatitis Indiana virus | 1 | 1974 | 13 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2764 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2014 | 113 | 0.030 |
Why?
| | Reticulocytes | 1 | 1974 | 16 | 0.030 |
Why?
| | Virus Attachment | 1 | 2013 | 11 | 0.030 |
Why?
| | Heparitin Sulfate | 1 | 2013 | 39 | 0.030 |
Why?
| | Virus Internalization | 1 | 2013 | 40 | 0.030 |
Why?
| | Precipitin Tests | 1 | 1993 | 88 | 0.030 |
Why?
| | Static Electricity | 1 | 2013 | 112 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2013 | 143 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 2700 | 0.030 |
Why?
| | Cell Fusion | 1 | 1993 | 50 | 0.030 |
Why?
| | Protein Binding | 2 | 2009 | 1888 | 0.030 |
Why?
| | Conserved Sequence | 1 | 1993 | 218 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 284 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2014 | 186 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 549 | 0.030 |
Why?
| | Endosomes | 1 | 2013 | 122 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2013 | 157 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1993 | 138 | 0.030 |
Why?
| | Proteolysis | 1 | 2012 | 142 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 129 | 0.020 |
Why?
| | Caspases | 1 | 2012 | 243 | 0.020 |
Why?
| | Viral Structural Proteins | 1 | 1991 | 12 | 0.020 |
Why?
| | Complement C5a | 1 | 2011 | 59 | 0.020 |
Why?
| | Poultry | 1 | 1990 | 9 | 0.020 |
Why?
| | Orthomyxoviridae | 1 | 1991 | 35 | 0.020 |
Why?
| | Tritium | 2 | 1985 | 66 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 26605 | 0.020 |
Why?
| | Orthomyxoviridae Infections | 1 | 2011 | 54 | 0.020 |
Why?
| | DNA | 2 | 1988 | 1350 | 0.020 |
Why?
| | Insulin | 1 | 2000 | 2080 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2001 | 3039 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1985 | 315 | 0.020 |
Why?
| | Vaccines, Synthetic | 1 | 1990 | 124 | 0.020 |
Why?
| | Polyribosomes | 2 | 1984 | 22 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 292 | 0.020 |
Why?
| | Chloramphenicol O-Acetyltransferase | 1 | 2009 | 38 | 0.020 |
Why?
| | Antibody Formation | 1 | 1990 | 266 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 72 | 0.020 |
Why?
| | Receptors, CCR | 1 | 2008 | 7 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2008 | 25 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 128 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1368 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1757 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 282 | 0.020 |
Why?
| | Seasons | 1 | 2011 | 440 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2009 | 137 | 0.020 |
Why?
| | Neurons | 1 | 2015 | 1277 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 924 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 384 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 8614 | 0.020 |
Why?
| | Mitochondrial Membranes | 1 | 2008 | 32 | 0.020 |
Why?
| | Genes | 1 | 1988 | 223 | 0.020 |
Why?
| | Protein Conformation | 2 | 1992 | 803 | 0.020 |
Why?
| | DNA, Recombinant | 1 | 1986 | 41 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1986 | 187 | 0.020 |
Why?
| | Mercaptoethanol | 1 | 1985 | 11 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2006 | 117 | 0.020 |
Why?
| | Disulfides | 1 | 1985 | 90 | 0.020 |
Why?
| | Fucose | 1 | 1985 | 3 | 0.020 |
Why?
| | Immune System | 1 | 2006 | 171 | 0.010 |
Why?
| | Poly A | 1 | 1984 | 45 | 0.010 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 44 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2004 | 47 | 0.010 |
Why?
| | Receptor, Insulin | 1 | 2004 | 93 | 0.010 |
Why?
| | Computational Biology | 1 | 2008 | 528 | 0.010 |
Why?
| | Xenopus laevis | 1 | 2004 | 115 | 0.010 |
Why?
| | RNA | 1 | 2010 | 806 | 0.010 |
Why?
| | Response Elements | 1 | 2004 | 82 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1518 | 0.010 |
Why?
| | Models, Genetic | 1 | 2006 | 559 | 0.010 |
Why?
| | Adult | 2 | 2021 | 30375 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2004 | 796 | 0.010 |
Why?
| | Basal Ganglia | 1 | 2001 | 44 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1228 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2322 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2004 | 1011 | 0.010 |
Why?
| | Carcinoma, Krebs 2 | 1 | 1974 | 1 | 0.010 |
Why?
| | Electrophoresis, Paper | 1 | 1974 | 1 | 0.010 |
Why?
| | Chromatography, Paper | 1 | 1974 | 3 | 0.010 |
Why?
| | Sulfur Radioisotopes | 1 | 1974 | 17 | 0.010 |
Why?
| | Hydroxyapatites | 1 | 1974 | 12 | 0.010 |
Why?
| | Chromatography | 1 | 1974 | 23 | 0.010 |
Why?
| | Peptide Biosynthesis | 1 | 1974 | 13 | 0.010 |
Why?
| | Carbon Radioisotopes | 1 | 1974 | 36 | 0.010 |
Why?
| | Triticum | 1 | 1974 | 9 | 0.010 |
Why?
| | Tissue Extracts | 1 | 1974 | 19 | 0.010 |
Why?
| | Autoradiography | 1 | 1974 | 69 | 0.010 |
Why?
| | Cell-Free System | 1 | 1974 | 47 | 0.010 |
Why?
| | Peptide Chain Initiation, Translational | 1 | 1974 | 38 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 1992 | 62 | 0.010 |
Why?
| | Viral Matrix Proteins | 1 | 1992 | 24 | 0.010 |
Why?
| | Rabbits | 1 | 1974 | 733 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1992 | 323 | 0.010 |
Why?
|
|
Morrison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|